RELMADA THERAPEUTICS, INC. (RLMD) Insider Trading & SEC Filings
Last SEC filing
RELMADA THERAPEUTICS, INC. (RLMD) - no SEC Form 4 insider filings recorded in the last 90 days. 3 Form 8-K material event filings were reported by RLMD in the last 90 days. InsiderAlpha tracks every RLMD SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About RELMADA THERAPEUTICS, INC. (RLMD)
RELMADA THERAPEUTICS, INC. trades under the ticker RLMD. InsiderAlpha tracks 14 primary SEC Form 4 filings from 7 reporting insiders for RLMD since 2024, sourced directly from SEC EDGAR.
| Sector | Health Care insider trading |
|---|---|
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
| SEC CIK | 0001553643 |
90-Day SEC Filing Activity
| Form 8-K filings (90d) | 3 |
|---|---|
| Latest Form 4 filing | 2025-12-16 |
Recent RLMD Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Maged Shenouda | Chief Financial Officer | P - Open-market purchase | 11.7K | $4.12 | $48K | SEC | |
| Sergio Traversa | Chief Executive Officer | P - Open-market purchase | 27.5K | $4.12 | $113K | SEC | |
| Maged Shenouda | Chief Financial Officer | P - Open-market purchase | 500.0K | $2.20 | $1.10M | SEC | |
| Paul Edward Kelly | Chief Operating Officer | P - Open-market purchase | 90.0K | $2.20 | $198K | SEC | |
| Sergio Traversa | Chief Executive Officer | P - Open-market purchase | 272.5K | $2.20 | $600K | SEC | |
| Chuck Ence | CAO and COO | P - Open-market purchase | 136.0K | $2.20 | $299K | SEC | |
| Sergio Traversa | Chief Executive Officer | P - Open-market purchase | 56.0K | $0.74 | $41K | SEC | |
| Sergio Traversa | Chief Executive Officer | P - Open-market purchase | 129.5K | $0.67 | $87K | SEC | |
| Sergio Traversa | Chief Executive Officer | P - Open-market purchase | 80.5K | $0.62 | $50K | SEC | |
| Charles J. Casamento | Director | G - Bona-fide gift | 13.0K | $0.00 | - | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for RELMADA THERAPEUTICS, INC. (RLMD). Updated in real time as new filings are submitted to the SEC.
Recent RLMD Form 8-K Material Events
- - Item 7.01, 9.01 [SEC]
- - Item 5.03, 5.07, 9.01 [SEC]
- - Item 2.02, 7.01, 9.01 [SEC]
- - Item 2.02, 7.01, 9.01 · Earnings · neutral [SEC]
Relmada Therapeutics issued a press release on March 19, 2026, providing a corporate update and reporting financial results for the fiscal year ended December 31, 2025. The company also updated its corporate presentation and conducted a conference call to discuss the results, wit - - Item 1.01, 3.02, 7.01, 8.01, 9.01 · Financing · positive [SEC]
Relmada Therapeutics entered into a Securities Purchase Agreement for a private placement of approximately $160 million in gross proceeds, consisting of 29.5 million shares at $4.75 per share and pre-funded warrants to purchase 4.2 million additional shares. The company intends t
Recent Insider Filings
- - Sergio Traversa (Chief Executive Officer)
- - Maged Shenouda (Chief Financial Officer)
- - John Glasspool (Director)
- - Paul Edward Kelly (COO)
- - Charles J. Casamento (Director)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in RLMD insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
RLMD Insider Trading - FAQ
- What is the latest insider trade for RLMD?
- RELMADA THERAPEUTICS, INC. (RLMD) had 0 insider filings in the last 90 days, with the most recent on 2025-12-16. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying RLMD stock?
- 0 insider purchases of RLMD were filed in the last 90 days.
- How many insiders are selling RLMD stock?
- 0 insider sales of RLMD were filed in the last 90 days.
- Where can I see RLMD SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks RLMD Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $RNAC Cartesian Therapeutics, Inc.
- $RNTX Rein Therapeutics, Inc.
- $RVMD Revolution Medicines, Inc.
- $SCLX Scilex Holding Co
- $SDEV Stablecoin Development Corp
- $SEPN Septerna, Inc.
- $SHPH Shuttle Pharmaceuticals Holdings, Inc.
- $SI SHOULDER INNOVATIONS, INC.
- $SMMT Summit Therapeutics Inc.
- $SMNR Semnur Pharmaceuticals, Inc.
Related Companies - Recent Insider Activity
- UNITED THERAPEUTICS Corp (UTHR)
- Liquidia Corp (LQDA)
- BeOne Medicines Ltd. (ONC)
- PERRIGO Co plc (PRGO)
- Processa Pharmaceuticals, Inc. (PCSA)
- Nuvalent, Inc. (NUVL)
- CYTOKINETICS INC (CYTK)
- Elanco Animal Health Inc (ELAN)
- Avalo Therapeutics, Inc. (AVTX)
- NATURES SUNSHINE PRODUCTS INC (NATR)
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live RLMD dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.